Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

H.C. Wainwright & Co. – August 17, 2022 – Article

Webcast Link to Second Quarter 2022 Earnings Financial Results Conference Call – Tuesday, August 16, 2022 at 8:30 a.m. ET

Corporate Presentation May 2022

Corporate-Presentation-May-2022

Webcast Link to First Quarter 2022 Earnings Financial Results Conference Call – Tuesday, May 17, 2022 at 8:30 a.m. ET

BP1003 AACR 2022 Abstract

BP1003-AACR-2022-Abstract

Webcast Link to 2021 Full Year Earnings Financial Results Conference Call – Friday, March 11, 2022 at 8:30 a.m. ET

Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2.

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery

Gagliardi M, Ashizawa AT. Biomedicines. 2021;9(4):433.

Annual Shareholders Presentation Slides – December 2020

View document

STONEGATE Capital Partners December 4, 2019 Report

Go to Stonegate Capital Report

Bio-Path Holdings

All Rights Reserved

Office:

4710 Bellaire Blvd, Suite 210
Bellaire, TX 77401

T: (832) 742-1357

R&D:

5455 Dashwood Street, Suite 300
Bellaire, TX 77401

T: (832) 742-1357

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us